Malignant T cell amplified sequence 1 (MCTS1) (NM_014060) Human Tagged ORF Clone Lentiviral Particle

CAT#: RC200224L4V

  • LentiORF®

Lenti ORF particles, MCTS1 (mGFP-tagged) - Human malignant T cell amplified sequence 1 (MCTS1), transcript variant 1, 200ul, >10^7 TU/mL

ORF Plasmid: DDK tGFP



Need custom lentivirus service?
Get a free quote

CNY 8,360.00


货期*
详询

规格
    • 200 ul

Product images

经常一起买 (3)
Lenti ORF control particles of pLenti-C-mGFP-P2A-Puro, >1x10^7 TU/ml, 0.5 ml
    • 500 ul

CNY 2,950.00


One-Wash Lentivirus Titer Kit, HIV-1 p24 ELISA
    • 96 reactions

CNY 5,230.00


MCTS1 mouse monoclonal antibody, clone OTI2F9 (formerly 2F9)
    • 100 ul

CNY 1,999.00
CNY 2,700.00

Specifications

Product Data
Product Name Malignant T cell amplified sequence 1 (MCTS1) (NM_014060) Human Tagged ORF Clone Lentiviral Particle
Synonyms MCT-1; MCT1
Vector pLenti-C-mGFP-P2A-Puro
ACCN NM_014060
ORF Size 543 bp
Sequence Data
The ORF insert of this clone is exactly the same as(RC200224).
OTI Disclaimer The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
Reference Data
RefSeq NM_014060.1
RefSeq Size 9805 bp
RefSeq ORF 546 bp
Locus ID 28985
Domains PUA
Protein Families Druggable Genome
MW 20.6 kDa
Gene Summary Anti-oncogene that plays a role in cell cycle regulation; decreases cell doubling time and anchorage-dependent growth; shortens the duration of G1 transit time and G1/S transition. When constitutively expressed, increases CDK4 and CDK6 kinases activity and CCND1/cyclin D1 protein level, as well as G1 cyclin/CDK complex formation. Involved in translation initiation; promotes recruitment of aminoacetyled initiator tRNA to P site of 40S ribosomes. Can promote release of deacylated tRNA and mRNA from recycled 40S subunits following ABCE1-mediated dissociation of post-termination ribosomal complexes into subunits. Plays a role as translation enhancer; recruits the density-regulated protein/DENR and binds to the cap complex of the 5'-terminus of mRNAs, subsequently altering the mRNA translation profile; up-regulates protein levels of BCL2L2, TFDP1, MRE11, CCND1 and E2F1, while mRNA levels remains constant. Hyperactivates DNA damage signaling pathway; increased gamma-irradiation-induced phosphorylation of histone H2AX, and induces damage foci formation. Increases the overall number of chromosomal abnormalities such as larger chromosomes formation and multiples chromosomal fusions when overexpressed in gamma-irradiated cells. May play a role in promoting lymphoid tumor development: lymphoid cell lines overexpressing MCTS1 exhibit increased growth rates and display increased protection against apoptosis. May contribute to the pathogenesis and progression of breast cancer via promotion of angiogenesis through the decline of inhibitory THBS1/thrombospondin-1, and inhibition of apoptosis. Involved in the process of proteasome degradation to down-regulate Tumor suppressor p53/TP53 in breast cancer cell; Positively regulates phosphorylation of MAPK1 and MAPK3. Involved in translation initiation; promotes aminoacetyled initiator tRNA to P site of 40S ribosomes. Can promote release of deacylated tRNA and mRNA from recycled 40S subunits following ABCE1-mediated dissociation of post-termination ribosomal complexes into subunits.[UniProtKB/Swiss-Prot Function]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

其它Malignant T cell amplified sequence 1产品

Customer Reviews 
Loading...